ZIVO Bioscience, Inc. (ZIVO)
USD 16.02
(-15.68%)
USD 16.02
(-15.68%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 555.71 Thousand USD | -73.82% |
| 2022 | 2.12 Million USD | -76.39% |
| 2021 | 8.99 Million USD | 3983.12% |
| 2020 | 220.17 Thousand USD | -40.39% |
| 2019 | 369.39 Thousand USD | -10.23% |
| 2018 | 411.5 Thousand USD | -90.23% |
| 2017 | 4.21 Million USD | 471.02% |
| 2016 | 737.29 Thousand USD | 914.44% |
| 2015 | 72.68 Thousand USD | -28.65% |
| 2014 | 101.85 Thousand USD | -95.32% |
| 2013 | 2.17 Million USD | 829.22% |
| 2012 | 234 Thousand USD | -49.51% |
| 2011 | 463.49 Thousand USD | 36.35% |
| 2010 | 339.92 Thousand USD | -15.4% |
| 2009 | 401.79 Thousand USD | -7.66% |
| 2008 | 435.14 Thousand USD | 58.32% |
| 2007 | 274.84 Thousand USD | -14.62% |
| 2006 | 321.92 Thousand USD | -51.22% |
| 2005 | 659.93 Thousand USD | 1142.03% |
| 2004 | 53.13 Thousand USD | 439.65% |
| 2003 | 9846.00 USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 816.39 Thousand USD | 46.91% |
| 2024 Q2 | 575.58 Thousand USD | -29.5% |
| 2023 Q2 | 710.33 Thousand USD | -37.03% |
| 2023 Q1 | 1.12 Million USD | -46.87% |
| 2023 FY | 555.71 Thousand USD | -73.82% |
| 2023 Q4 | 555.71 Thousand USD | -73.56% |
| 2023 Q3 | 2.1 Million USD | 195.92% |
| 2022 Q3 | 3.97 Million USD | -32.28% |
| 2022 FY | 2.12 Million USD | -76.39% |
| 2022 Q1 | 7.68 Million USD | -14.48% |
| 2022 Q2 | 5.86 Million USD | -23.72% |
| 2022 Q4 | 2.12 Million USD | -46.54% |
| 2021 Q3 | 10.97 Million USD | -1.19% |
| 2021 Q1 | 648.88 Thousand USD | 194.71% |
| 2021 Q2 | 11.1 Million USD | 1611.19% |
| 2021 FY | 8.99 Million USD | 3983.12% |
| 2021 Q4 | 8.99 Million USD | -18.06% |
| 2020 FY | 220.17 Thousand USD | -40.39% |
| 2020 Q4 | 220.17 Thousand USD | 68.8% |
| 2020 Q1 | 178.91 Thousand USD | -51.56% |
| 2020 Q2 | 222.7 Thousand USD | 24.47% |
| 2020 Q3 | 130.44 Thousand USD | -41.43% |
| 2019 Q3 | 69.9 Thousand USD | -37.72% |
| 2019 Q1 | 103.76 Thousand USD | -74.79% |
| 2019 Q2 | 112.22 Thousand USD | 8.16% |
| 2019 Q4 | 369.39 Thousand USD | 428.45% |
| 2019 FY | 369.39 Thousand USD | -10.23% |
| 2018 Q2 | 739.67 Thousand USD | -73.46% |
| 2018 FY | 411.5 Thousand USD | -90.23% |
| 2018 Q4 | 411.5 Thousand USD | 47.74% |
| 2018 Q1 | 2.78 Million USD | -33.8% |
| 2018 Q3 | 278.53 Thousand USD | -62.34% |
| 2017 Q4 | 4.21 Million USD | 194.58% |
| 2017 FY | 4.21 Million USD | 471.02% |
| 2017 Q2 | 205.54 Thousand USD | -83.41% |
| 2017 Q1 | 1.23 Million USD | 68.01% |
| 2017 Q3 | 1.42 Million USD | 595.33% |
| 2016 Q1 | 349.59 Thousand USD | 381.01% |
| 2016 Q2 | 90.84 Thousand USD | -74.01% |
| 2016 Q3 | 749.91 Thousand USD | 725.47% |
| 2016 Q4 | 737.29 Thousand USD | -1.68% |
| 2016 FY | 737.29 Thousand USD | 914.44% |
| 2015 Q3 | 101.79 Thousand USD | -14.63% |
| 2015 Q4 | 72.68 Thousand USD | -28.6% |
| 2015 Q1 | 183.03 Thousand USD | 79.69% |
| 2015 FY | 72.68 Thousand USD | -28.65% |
| 2015 Q2 | 119.24 Thousand USD | -34.85% |
| 2014 FY | 101.85 Thousand USD | -95.32% |
| 2014 Q4 | 101.85 Thousand USD | -93.61% |
| 2014 Q1 | 1.78 Million USD | -17.97% |
| 2014 Q2 | 1.54 Million USD | -13.6% |
| 2014 Q3 | 1.59 Million USD | 3.37% |
| 2013 FY | 2.17 Million USD | 829.22% |
| 2013 Q3 | 2.01 Million USD | 305.3% |
| 2013 Q2 | 496.2 Thousand USD | 124.29% |
| 2013 Q4 | 2.17 Million USD | 8.12% |
| 2013 Q1 | 221.23 Thousand USD | -5.46% |
| 2012 FY | 234 Thousand USD | -49.51% |
| 2012 Q4 | 234 Thousand USD | 2.24% |
| 2012 Q3 | 228.87 Thousand USD | -35.77% |
| 2012 Q2 | 356.31 Thousand USD | -14.64% |
| 2012 Q1 | 417.42 Thousand USD | -9.94% |
| 2011 Q3 | 366.05 Thousand USD | -6.34% |
| 2011 Q4 | 463.49 Thousand USD | 26.62% |
| 2011 FY | 463.49 Thousand USD | 36.35% |
| 2011 Q2 | 390.84 Thousand USD | 4.18% |
| 2011 Q1 | 375.15 Thousand USD | 10.36% |
| 2010 Q1 | 583.36 Thousand USD | 45.19% |
| 2010 Q3 | 318.88 Thousand USD | -18.87% |
| 2010 Q4 | 339.92 Thousand USD | 6.6% |
| 2010 FY | 339.92 Thousand USD | -15.4% |
| 2010 Q2 | 393.05 Thousand USD | -32.62% |
| 2009 Q4 | 401.79 Thousand USD | -36.33% |
| 2009 Q1 | 366.58 Thousand USD | -15.76% |
| 2009 FY | 401.79 Thousand USD | -7.66% |
| 2009 Q2 | 403.16 Thousand USD | 9.98% |
| 2009 Q3 | 631.04 Thousand USD | 56.52% |
| 2008 Q1 | 332.56 Thousand USD | 21.0% |
| 2008 FY | 435.14 Thousand USD | 58.32% |
| 2008 Q4 | 435.14 Thousand USD | -6.42% |
| 2008 Q3 | 464.97 Thousand USD | 1.08% |
| 2008 Q2 | 460 Thousand USD | 38.32% |
| 2007 Q1 | 877.99 Thousand USD | 172.74% |
| 2007 FY | 274.84 Thousand USD | -14.62% |
| 2007 Q4 | 274.84 Thousand USD | -44.42% |
| 2007 Q3 | 494.5 Thousand USD | 25.5% |
| 2007 Q2 | 394.03 Thousand USD | -55.12% |
| 2006 Q2 | 487.81 Thousand USD | 157.22% |
| 2006 FY | 321.92 Thousand USD | -51.22% |
| 2006 Q4 | 321.92 Thousand USD | -48.79% |
| 2006 Q3 | 628.63 Thousand USD | 28.87% |
| 2006 Q1 | 189.64 Thousand USD | -71.26% |
| 2005 Q2 | 154.6 Thousand USD | 439.25% |
| 2005 Q1 | 28.67 Thousand USD | -46.04% |
| 2005 Q4 | 659.93 Thousand USD | 1362.63% |
| 2005 Q3 | 45.12 Thousand USD | -70.82% |
| 2005 FY | 659.93 Thousand USD | 1142.03% |
| 2004 FY | 53.13 Thousand USD | 439.65% |
| 2004 Q4 | 53.13 Thousand USD | 9.62% |
| 2004 Q3 | 48.47 Thousand USD | -95.46% |
| 2004 Q2 | 1.06 Million USD | 40.74% |
| 2004 Q1 | 758.48 Thousand USD | 7603.48% |
| 2003 Q4 | 9846.00 USD | 0.0% |
| 2003 FY | 9846.00 USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -85.778% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 90.312% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 96.218% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 98.22% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 82.742% |
| Better Therapeutics, Inc. | 22.94 Million USD | 97.578% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 98.062% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 85.09% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 97.295% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 97.369% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 99.138% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | 76.39% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 99.217% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 97.874% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -631.271% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 95.433% |
| Molecular Templates, Inc. | 35.38 Million USD | 98.429% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | 87.288% |
| NexImmune, Inc. | 8.59 Million USD | 93.534% |
| Orgenesis Inc. | 14.55 Million USD | 96.181% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 95.291% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -345.845% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 90.217% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -41.668% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.882% |
| Statera Biopharma, Inc. | 21.16 Million USD | 97.375% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 94.501% |
| Trevena, Inc. | 40.6 Million USD | 98.631% |
| Vaxxinity, Inc. | 44.35 Million USD | 98.747% |
| Vaccinex, Inc. | 3.63 Million USD | 84.695% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -1301.339% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 99.02% |